Sanofi (SNY) to Release Quarterly Earnings on Friday

Sanofi (NASDAQ:SNY) will likely be releasing its Q3 2025 results before the market opens on Friday, October 24th. Analysts expect the company to announce earnings of $1.65 per share and revenue of $12.6208 billion for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Friday, October 24, 2025 at 8:30 AM ET.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.Sanofi’s revenue was down 7.0% on a year-over-year basis. During the same period last year, the business earned $1.73 EPS. On average, analysts expect Sanofi to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Sanofi Stock Performance

NASDAQ:SNY opened at $49.99 on Thursday. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The firm’s fifty day simple moving average is $48.60 and its 200 day simple moving average is $49.55. The stock has a market cap of $122.75 billion, a P/E ratio of 12.02, a price-to-earnings-growth ratio of 1.20 and a beta of 0.51. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SNY. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $56.00 to $58.00 in a research report on Monday, September 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Finally, Barclays restated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Sanofi currently has a consensus rating of “Buy” and an average price target of $62.67.

Institutional Investors Weigh In On Sanofi

Large investors have recently modified their holdings of the business. Raymond James Financial Inc. increased its position in shares of Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after acquiring an additional 2,635,867 shares during the last quarter. HRT Financial LP acquired a new position in shares of Sanofi during the 2nd quarter worth about $5,884,000. Vident Advisory LLC lifted its position in Sanofi by 717.0% in the second quarter. Vident Advisory LLC now owns 127,131 shares of the company’s stock valued at $6,142,000 after acquiring an additional 111,571 shares during the last quarter. AQR Capital Management LLC grew its stake in Sanofi by 138.2% during the 2nd quarter. AQR Capital Management LLC now owns 72,698 shares of the company’s stock worth $3,512,000 after buying an additional 42,180 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Sanofi in the 2nd quarter valued at approximately $848,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.